The July 27, 2026, stock crash occurred after FDA staff issued a scathing review of Deramiocel, citing insufficient evidence regarding cardiac endpoints and concerns over post-randomization statistical adjustments. Law firm Levi & Korsinsky is now examining whether Capricor executives, including CEO Linda Marbán, suppressed material risks while maintaining a positive narrative to the public.
Capricor Faces Shareholder Investigation After Deramiocel Data Warning
A 70% collapse in Capricor Therapeutics stock has triggered a formal investigation into whether the company misled investors regarding the efficacy of its lead drug, Deramiocel. The probe follows the release of FDA briefing documents that contradicted the firm's previous optimistic disclosures about cardiac performance and regulatory feedback.
Prior to the market rout, the company had touted promising results, claiming in May 2026 that the therapy slowed cardiac decline by roughly 91% compared to a placebo. Investors who incurred losses during this period are now being reviewed for potential legal action, with the inquiry centering on whether those earlier statements obscured the true state of the FDA’s review process.
Comments (0)
No comments yet. Be the first!